In a study involving 216 patients with schizophrenia, researchers investigated the link between polymorphisms in oxidative stress-related genes and adenosine receptor gene with tardive dyskinesia (TD) occurrence and cognitive impairments. Patients were separated into two groups: TD group (n=157) and non-TD group (n=59). The extraction of DNA was completed by using a high-salt method, as well as SNP genotyping. The Abnormal Involuntary Movement Scale, Positive and Negative Syndrome Scale, and Repeated Battery for Assessment of Neuropsychological Status were used to measure TD severity, psychopathology, and cognitive functioning. In this group of patients, it was found that the interaction of oxidative stress-related genes and adenosine receptor gene might contribute to TD susceptibility and severity.
Authors of a review aimed to explore the clinical utility of deutetrabenazine in Huntington’s Disease (HD) and tardive dyskinesia (TD). Through summarizing clinical evidence, the authors walked through the efficacy in both disease types. Overall, the authors sited deutetrabenazine to be a safe and effective treatment for both TD and chorea in HD, with indirect comparisons showing relative superiority of deutetrabenazine over tetrabenazine for safety, though they do note that direct comparisons of efficacy and safety is needed between VMAT2 and dopamine blocking agents.
In a video from Medpage Today, Peter Weiden, MD, comments on staying updated on new antipsychotic drugs and medical practices. He notes that he has learned from online resources
DelveInsight’s 2023 Report Reveals a Thriving Dyskinesia Pipeline With Over 45 Innovative Drugs Under Development by 40+ Key Players
The “Dyskinesia Pipeline Insight 2023” report from DelveInsight offers an in-depth analysis of the dyskinesia treatment landscape, highlighting 40+ companies and 45+ pipeline drugs ranging from clinical to nonclinical stages. Significant updates include a phase 2 study by Intra-Cellular Therapeutics for lenrispodun in August 2023, and a phase 3 trial for Teva’s TEV-50717 in September 2023, focusing on efficacy and safety for patients with dyskinesia.
Dr. Stacy Finkbeiner Explores the Effects of Tardive Dyskinesia on Life’s Key Domains in a Groundbreaking Study
In this YouTube video, Stacy Finkbeiner, PhD, discusses a study published in The Journal of Clinical Psychiatry on the profound impact of tardive dyskinesia (TD) on patients’ lives across physical, psychological, social, and professional realms. The survey, conducted in the United States, reveals that TD significantly impacts various aspects of life, including motor function, sleep, emotional well-being, social interaction, and employment. Notably, over one-third of those surveyed have skipped or ceased their medication due to the severity of their TD symptoms.
In a study, 269 patients with tardive dyskinesia (TD) were surveyed to evaluate the disorder’s impact on their quality of life. The findings revealed that most patients experienced moderate-to-severe physical challenges due to TD, including difficulties with speaking, eating, and sleeping. Psychologically, patients felt embarrassed and anxious, leading to social withdrawal. Socially, TD impacted patients’ relationships and increased stigma. Professionally, it led to significant work impairment and hindered career progress.
The study emphasizes that TD’s effects are diverse and profound, influencing more than just motor functions and significantly reducing patients’ overall wellbeing and daily life.
A recent case report assessed an 80-year-old man with a history of dementia, bilateral blindness, glaucoma, hearing loss, hypertension, and hypercholesterolemia complaining of visual hallucinations. Risperidone was first prescribed, followed by a combination with Quetiapine, and eventually replaced with valproate due to lack of symptom improvement and non-adherence. Three months after stopping antipsychotic medications, he developed orofacial tremors.
Researchers concluded that, when prescribing antipsychotics, physicians must be cautious of tardive dyskinesia (TD) as a potential delayed side effect, and physicians need to monitor for early signs of TD, especially in high-risk individuals. In this case, risk factors included old age, prolonged risperidone use, and abrupt cessation of the drug.
Pharmacogenomics Report Reveals Key Gene-Drug Interactions in Antipsychotics; Dosage Guidance Recognized by Major Health Organizations
A recent report examined the field of pharmacogenomics and its application to psychotropic medications; specifically, the gene-drug interactions between CYP2D6, CYP3A4, and CYP1A2 with antipsychotics. The report found that CYP2D6 phenotypes impact plasma concentration levels and therapeutic outcomes for various antipsychotics, CYP3A4 has shown significant interactions with quetiapine, and CYP1A2 doesn’t display significant differences in pharmacokinetics for drugs like clozapine or olanzapine.
The report concluded that significant organizations such as the Clinical Pharmacogenetics Implementation Consortium, FDA, and Dutch Pharmacogenetics Working Group recognize the importance of using pharmacogenomics, which can be essential in guiding dosing and minimizing the risk of adverse effects with antipsychotic medications due to its influence on pharmacokinetics.
In a study, researchers reviewed the symptoms, causes, and treatment of vocal tics, which are characterized by involuntary verbal sounds or words ranging from subtle to pronounced. Researchers noted that tic disorders, including Tourette’s syndrome, are among the diagnostic criteria for such conditions, often originating in childhood, but possibly emerging in adulthood. Vocal tics can also accompany conditions like attention deficit hyperactivity disorder, autism, obsessive-compulsive disorder, schizophrenia, or traumatic brain injury. Some medications, including antipsychotics, anticonvulsants, and antidepressants may induce tics. Medications like aripiprazole or haloperidol, and therapy such as comprehensive behavioral intervention for tics, can help manage tics and their impact on daily life.
Acknowledging that diagnosing tardive dyskinesia (TD) can be challenging since its symptoms can be confused with those of mental illness or other drug side effects, Medscape offers a quiz to test the knowledge of the differential diagnosis of TD.
Multiple choice questions of the “Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis” include: “Which signs and symptoms are most indicative of TD,” “Which observation helps distinguish tardive tremors from cerebellar or psychogenic tremors,” and more.